TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
BBOT · Nasdaq · United States
Share price · BBOT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BBOT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026+16.4%
- 9 Nov 2026+12.7%
Nothing announced by BBOT that day or the session before.
- 2 Nov 2026-11.8%
Nothing announced by BBOT that day or the session before.
- 11 Sep 2026-10.3%
Nothing announced by BBOT that day or the session before.
- 10 Sep 2026-18.3%
Nothing announced by BBOT that day or the session before.
- 9 Sep 2026-23.8%
- 8 Jul 2026+8.8%
Nothing announced by BBOT that day or the session before.
- 26 Jun 2026-3.8%
Nothing announced by BBOT that day or the session before.
- 9 Jun 2026-6.7%
Nothing announced by BBOT that day or the session before.
- 14 May 2026+5.3%
Nothing announced by BBOT that day or the session before.
Share of unusual movement by asset
For each asset, the share of BBOT's own-move activity since 7 Aug 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
BBO-10203events and moves
| 1 | shown from 8 days |
BBO-11818events and moves
| 1 | shown from 8 days |
BBO-8520events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 8% |
| Other company news (earnings, financing, releases naming no asset) | — | 10% |
| Sessions with no dated event | — | 82% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | RAS:PI3Kα protein-protein interactionSmall molecule | Non-Small Cell Lung CancerBreast CancerColorectal Cancer HR+/HER2- Metastatic Breast Cancer, HER2-Positive Breast Cancer | |
| Phase 1 | Pan-KRASSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (11)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $30M | $77M+ $117M short-term inv. | $34M-$28M operating cash flow | report ↗ |
View 10 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $49M | $54M+ $172M short-term inv. | $56M-$44M operating cash flow | report ↗ |
| 2026-Q1 | — | $40M | $53M+ $200M short-term inv. | $42M-$36M operating cash flow | report ↗ |
| 2025-Q4 | — | $38M | $374M+ $52M short-term inv. | $39M-$42M operating cash flow | report ↗ |
| 2025-Q3 | — | $35M | $409M+ $60M short-term inv. | $45M-$71M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $0.7M | —-$0.3M operating cash flow | report ↗ |
| 2025-Q1 | — | $21M | $1.0M | $0.5M-$0.7M operating cash flow | report ↗ |
| 2024-Q4 | — | $20M | $1.7M+ $125M short-term inv. | $20M-$0.1M operating cash flow | report ↗ |
| 2024-Q3 | — | $18M | $1.8M | —-<$0.1M operating cash flow | report ↗ |
| 2024-Q2 | — | — | $1.8M | —-<$0.1M operating cash flow | report ↗ |
| 2024-Q1 | — | — | $1.8M | —-$0.6M operating cash flow | report ↗ |
Annual history (3 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $121M | $374M+ $52M short-term inv. | $34M-$114M operating cash flow | report ↗ |
BBOT did not disclose revenue for 2025. R&D expenses were $121.2M, up 65.8% YoY from $73.11M, and the company reported a full-year net loss of $134.04M. Cash and equivalents were $373.82M as of December 31, 2025, while cash, cash equivalents, and marketable securities totaled $425.5M.
Management expects the cash runway to fund operations into 2028. Clinically, BBOT reported preliminary data across its three RAS-pathway programs: BBO-8520 showed a 65% objective response rate in KRAS G12C NSCLC with a potentially differentiated liver toxicity profile, BBO-11818 produced the first publicly disclosed confirmed panKRAS monotherapy partial response in pancreatic ductal adenocarcinoma, and BBO-10203 showed no hyperglycemia with full target engagement. Updated clinical readouts for all three programs are expected in the second half of 2026, with internal combination studies anticipated to open later in 2026. The company also completed its de-SPAC business combination with Helix Acquisition Corp. II and began trading as BBOT on Nasdaq in August 2025.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 1 sale ($185). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-13 | Cobo Marc · Principal Accounting Officer | Open-market sale | 78 | $2.37 | $185 | Form 4 |
| 2026-10-21 | Cobo Marc · Principal Accounting Officer | Tax withholding | 203 | $2.68 | $544 | Form 4 |
| 2026-10-01 | Ben Yong · Chief Med & Dev Officer | Tax withholding | 1,047 | $3.94 | $4K | Form 4 |
| 2026-10-01 | Beltran Pedro · director, President and CEO | Tax withholding | 1,047 | $3.94 | $4K | Form 4 |
| 2026-10-01 | Elmelech Idan · COO & Principal Financial Ofcr | Tax withholding | 343 | $3.94 | $1K | Form 4 |
| 2026-10-01 | Cobo Marc · Principal Accounting Officer | Tax withholding | 126 | $3.94 | $496 | Form 4 |
| 2026-09-10 | Cobo Marc · Principal Accounting Officer | Award / grant | 9,038 | — | — | Form 4 |
| 2026-09-10 | Cobo Marc · Principal Accounting Officer | Tax withholding | 203 | $5.52 | $1K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 66 reporting institutions held 57.5M shares ($510.0M, 71.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Cormorant Asset Management, LP | 17,878,594 | $160.0M |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4,885,446 | $43.7M |
| 3 | Omega Fund Management, LLC | 3,289,661 | $29.4M |
| 4 | EcoR1 Capital, LLC | 2,823,126 | $25.3M |
| 5 | Alphabet Inc. | 2,823,126 | $25.3M |
| 6 | WELLINGTON MANAGEMENT GROUP LLP | 2,818,348 | $25.2M |
| 7 | ENAVATE SCIENCES GP, LLC | 2,626,946 | $23.5M |
| 8 | CITADEL ADVISORS LLC | 2,528,762 | $22.6M |
| 9 | NOVO HOLDINGS A/S | 2,185,923 | $19.6M |
| 10 | BlackRock, Inc. | 2,088,297 | $18.7M |
| 11 | Laurion Capital Management LP | 1,922,656 | $17.2M |
| 12 | ARMISTICE CAPITAL, LLC | 1,328,000 | $11.9M |
| 13 | Aisling Capital Management LP | 1,018,018 | $9.1M |
| 14 | Paradigm Biocapital Advisors LP | 868,213 | $7.8M |
| 15 | Octagon Capital Advisors LP | 719,000 | $6.4M |